Sugi Predict

Sugi Predict / Compounds / SCHEMBL9516494

SCHEMBL9516494

SCHEMBL9516494

BrCCOCCOCc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 2/20 0.58
▸ NAAA Q02083 1/20 0.53
▸ SMN1; SMN2 Q16637 3/20 0.46
▸ NPC1 O15118 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ ALDH1A1 P00352 2/20 0.44
▸ TDP1 Q9NUW8 2/20 0.44
▸ IDO1 P14902 1/20 0.43
▸ TRPA1 O75762 1/20 0.42
▸ LTA4H P09960 1/20 0.42
▸ AGXT P21549 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ CA1 P00915 2/20 0.40
▸ CA2 P00918 2/20 0.40
▸ CA7 P43166 2/20 0.40
▸ CA9 Q16790 2/20 0.40
▸ HTT P42858 1/20 0.40
▸ HRH4 Q9H3N8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16437098 1.00 TSHR (0.58) TSHRNAAASMN1; SMN2NPC1MAPT
SCHEMBL1594369 1.00 TSHR (0.58) TSHRNAAASMN1; SMN2NPC1MAPT
SCHEMBL20120433 1.00 TSHR (0.58) TSHRNAAASMN1; SMN2NPC1MAPT
SCHEMBL9518715 1.00 TSHR (0.58) TSHRNAAASMN1; SMN2NPC1MAPT
SCHEMBL146520 0.96 TSHR (0.64) TSHRNAAASMN1; SMN2ALDH1A1TDP1
SCHEMBL11544338 0.93 TSHR (0.61) TSHRNAAASMN1; SMN2ALDH1A1TDP1
SCHEMBL24773684 0.92 TSHR (0.54) TSHRNAAASMN1; SMN2NPC1MAPT
SCHEMBL15140027 0.89 TSHR (0.47) TSHRNAAASMN1; SMN2NPC1MAPT
SCHEMBL15145980 0.89 TSHR (0.47) TSHRNAAASMN1; SMN2NPC1MAPT
SCHEMBL4608747 0.89 TSHR (0.74) TSHRNAAASMN1; SMN2TDP1IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260124309-A1 STAT6 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-05-07 — — US disclosed
WO-2025049820-A1 STAT6 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2025-03-06 — — WO disclosed
CN-110831589-B Medical compounds 维拉萨卢斯里切尔卡有限公司 2025-01-03 — — CN disclosed
CN-119137093-A Fluorine-containing ether compound, lubricant for magnetic recording medium, and magnetic recording medium 株式会社力森诺科 2024-12-13 — — CN disclosed
US-20240139164-A1 RAPAMYCIN ANALOGS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2024-05-02 — — US disclosed
US-20240131012-A1 RAPAMYCIN ANALOGS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2024-04-25 — — US disclosed
CN-117700374-A Preparation method of chiral high morpholine-3-formic acid 吉尔多肽生物制药(大连市)有限公司 2024-03-15 — — CN disclosed
CN-117510504-A Protein kinase degradation agent, medicine and application 深圳市新樾生物科技有限公司 2024-02-06 — — CN disclosed
WO-2023224093-A1 FLUORINE-CONTAINING ETHER COMPOUND, LUBRICANT FOR MAGNETIC RECORDING MEDIUM, AND MAGNETIC RECORDING MEDIUM 株式会社レゾナック 2023-11-23 — — WO disclosed
US-11819476-B2 Rapamycin analogs and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2023-11-21 — — US disclosed
WO-2019008537-A1 MEDICAL COMPOUNDS VERA SALUS RICERCA S.R.L. (IT) 2019-01-10 — — WO disclosed
US-9777020-B2 Furo-3-carboxamide derivatives and methods of use ABBVIE INC. (US) 2017-10-03 — — US disclosed
EP-3097095-A1 FURO-3-CARBOXAMIDE DERIVATIVES AND METHODS OF USE AbbVie Inc. (US) 2016-11-30 — — EP disclosed
US-20150210720-A1 FURO-3-CARBOXAMIDE DERIVATIVES AND METHODS OF USE ABBVIE INC. 2015-07-30 — — US disclosed
WO-2015112754-A1 FURO-3-CARBOXAMIDE DERIVATIVES AND METHODS OF USE ABBVIE INC. (US) 2015-07-30 — — WO disclosed
US-20080176341-A1 Method for Suppressing Intermolecular Nonspecific Interaction and for Intensifying Intermolecular Specific Interaction on Metal Surface REVERSE PROTEMICS RESEARCH INSTITUTE CO., LTD. (JP) 2008-07-24 — — US disclosed
EP-0341409-B1 Platinum (II) complexes, their preparation and use as antitumour agents BOEHRINGER MANNHEIM ITALIA (IT) 1993-12-29 — — EP disclosed
EP-0415939-A1 PLATINUM(II) COMPLEXES, THEIR PREPARATION AND USE AS ANTI-TUMOUR AGENTS BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) 1991-03-13 — — EP disclosed
EP-0341409-A1 Platinum (II) complexes, their preparation and use as antitumour agents BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) 1989-11-15 — — EP disclosed
WO-1989009218-A1 PLATINUM(II) COMPLEXES, THEIR PREPARATION AND USE AS ANTI-TUMOUR AGENTS BOEHRINGER BIOCHEMIA ROBIN S.P.A. (IT) 1989-10-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260124309-A1 STAT6 DEGRADERS AND USES THEREOF STAT6, NCOR2, NCOR1 TSHR 70/4885NAAA 3147/4885SMN1; SMN2 2865/4885
US-20240139164-A1 RAPAMYCIN ANALOGS AND USES THEREOF RICTOR, MTOR, RPTOR TSHR 3810/4885NAAA 3435/4885SMN1; SMN2 2228/4885
US-20150210720-A1 FURO-3-CARBOXAMIDE DERIVATIVES AND METHODS OF USE NTRK2, MUSK, NTRK3 TSHR 35/4885NAAA 1261/4885SMN1; SMN2 833/4885
US-20240131012-A1 RAPAMYCIN ANALOGS AND USES THEREOF RICTOR, MTOR, RPTOR TSHR 3810/4885NAAA 3435/4885SMN1; SMN2 2228/4885
US-11819476-B2 Rapamycin analogs and uses thereof RICTOR, MTOR, RPTOR TSHR 3531/4885NAAA 4312/4885SMN1; SMN2 2373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.